Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Instagram Outage Disrupts Thousands of U.S. Users 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
NEW YORK and MELBOURNE, Australia, Nov. 09, 2016 -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the first quarter ended September 30, 2016 and provide a corporate update beginning at 5:00 pm Eastern Time on Monday, November 14, 2016 and 9:00 am Australian Eastern Daylight Time on Tuesday, November 15, 2016.
To access the call, dial 1 855 881 1339 (toll-free US), 1 800 558 698 (toll-free Australia) or +61 2 9007 3187 (outside of the US and Australia).
The conference identification code is 912575.
The live webcast can be accessed via: http://webcasting.boardroom.media/broadcast/58214386d5f1311b35bd36a6
The conference call will be accompanied by a slide presentation. Please log in approximately 15 minutes prior to the scheduled start time.
The archived webcast will be available in the Events and Presentations section of the Investor page on the Company’s website – www.mesoblast.com
About Mesoblast
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory disorders, orthopedic disorders, and oncologic/hematologic conditions.
For further information, please contact: Julie Meldrum Global Head, Corporate Communications Mesoblast Limited T: +61 3 9639 6036 E: [email protected] Schond Greenway VP, Investor Relations Mesoblast Limited T: +1 212 880-2060 E: [email protected]
